Moderna Pharma has filed a complaint against companies Pfizer and BioNtech, which it accuses of violating. patent of mRNA that the company introduced between 2010 and 2016 as part of the development of mRNA technology. The patent was recently used in a vaccine against covid-19.

“We are filing these lawsuits to protect the groundbreaking mRNA technology platform we pioneered. millions of dollars “Moderna CEO Stéphane Bancel said in a statement.

According to Moderna’s complaint, US-based Pfizer and Germany’s BioNtech “illegally copied Moderna’s inventions. Moreover, they continued to use it without permission”said Shannon Thyme Klinger, the drugmaker’s chief legal officer.

“Moderna believes that Pfizer and BioNTech have copied two critically important key features of Moderna’s proprietary technologies. success of vaccines of mRNA”. The text was released this Friday and ensures that both companies lack the level of experience necessary to develop vaccines based on mRNA technology.

As long as the epidemic lasts

United States-based Massachusetts company, in October 2020 not claiming their rights on covid-19 related patents while the pandemic continues.

However, it claims to have updated that commitment in March 2022. He assured that he would not make any claims about it. 92 countries recognized as low income By the World Health Organization’s Covax program and the GAVI foundation.

In the note, Moderna claims that as of March this year, “the collective fight against covid-19 has entered a new phase and the supply of vaccines has ceased to be a barrier to access in many parts of the world.” Companies like Pfizer and BioNTech will respect intellectual property rights. They will also consider a commercially reasonable license if requested for other markets.”

With its complaint, Moderna emphasizes that it does not want Comarty, the trade name of the coronavirus vaccine developed by Pfizer and BioNTech, to be withdrawn. Nor do they want compensation for sales in 92 countries. Covax program promised to help distribute the vaccine.

Likewise, it states that its demands are limited to the period after March 2022.

Company making the application Complaints in the United States and Germanydoes not provide detailed information on the financial compensation required.